Cargando…

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer

AIM: We aimed to assess the role of 21-gene recurrence score (RS) in the decision-making for surgical treatment in early stage breast cancer and compared the outcomes between breast-conserving surgery (BCS) and mastectomy (MAST) among various 21-gene RS groups. METHODS: We included patients with sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, San-Gang, Zhang, Wen-Wen, Wang, Jun, Dong, Yong, Chen, Yong-Xiong, He, Zhen-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433114/ https://www.ncbi.nlm.nih.gov/pubmed/30962690 http://dx.doi.org/10.2147/OTT.S199625

Ejemplares similares

21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery
por: Wu, San-Gang, et al.
Publicado: (2019)

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
por: Zhou, Ping, et al.
Publicado: (2020)

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
por: Chen, Wei-Rong, et al.
Publicado: (2019)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
por: Wang, Jun, et al.
Publicado: (2018)

Prognostic validation and treatment decision making of the 8(th) edition of the American Joint Committee on Cancer pathological staging system for elderly women with early-stage breast cancer
por: Wu, San-Gang, et al.
Publicado: (2020)

Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer
por: Li, Guan-Qiao, et al.
Publicado: (2022)

Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy
por: Wu, San-Gang, et al.
Publicado: (2020)

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals
por: Martínez del Prado, Purificación, et al.
Publicado: (2018)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
por: Lian, Chen-Lu, et al.
Publicado: (2021)

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2019)

Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study
por: Liu, Kai-Hua, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

Omission of Postoperative Radiotherapy in Women Aged 65 Years or Older With Tubular Carcinoma of the Breast After Breast-Conserving Surgery
por: Wu, San-Gang, et al.
Publicado: (2018)

Prognostic validation and therapeutic decision‐making of the AJCC eighth pathological prognostic staging for T3N0 breast cancer after mastectomy
por: Wu, San‐Gang, et al.
Publicado: (2020)

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
por: Lee, Moo Hyun, et al.
Publicado: (2015)

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013
por: Parsons, Benjamin M., et al.
Publicado: (2016)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

Omission of adjuvant radiotherapy following breast-conserving surgery for elderly women with early-stage pure mucinous breast carcinoma
por: Wu, San-Gang, et al.
Publicado: (2019)

Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes
por: Li, Guan-Qiao, et al.
Publicado: (2023)

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2019)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2021)

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
por: Yang, David D., et al.
Publicado: (2020)

The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis
por: Wu, San-Gang, et al.
Publicado: (2017)

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
por: Barton, S, et al.
Publicado: (2012)

Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Makower, Della, et al.
Publicado: (2021)

Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis
por: Wu, San-Gang, et al.
Publicado: (2017)

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era
por: Mamounas, Eleftherios P., et al.
Publicado: (2018)

Treatment decision-making among breast cancer patients in Malaysia
por: Nies, Yong Hui, et al.
Publicado: (2017)

Promoting emancipated decision-making for surgical treatment of early stage breast cancer among Jordanian women
por: Obeidat, Rana F.
Publicado: (2015)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis
por: Makower, Della, et al.
Publicado: (2022)

The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
por: Thaker, Nikhil G, et al.
Publicado: (2015)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

Cost Evaluation During Decision-Making in Patients at Early Stages of Psychosis
por: Ermakova, Anna O., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_73f1q95pmqpbdnkqlu507ddimd